ConductScience.org, home

Paper34367161

TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer.

Ge Z and 3 others. Front Immunol, 2021. Cited by 199 papers, by iCite.

Cite this record

ConductScience Library. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer. Papers, record 34367161. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34367161

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer.
PubMed
Journal
Front Immunol
PubMed
Year
2021
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
Citations, by iCite
199
iCite
Relative citation ratio, by iCite
10.4
iCite
Revised in PubMed
2021-12-14
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ge ZZhouhong
2Peppelenbosch MPMaikel P
3Sprengers DDave
4Kwekkeboom JJaap

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Immune Checkpoint InhibitorsMajor topic
ImmunotherapyMajor topic
NeoplasmsMajor topic
Receptors, ImmunologicMajor topic
Animals
Humans

Source PubMed

Download CSV of topics

References101

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
123330003Nectin-2 and DDX3 are biomarkers for metastasis and poor prognosis of squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder.Int J Clin Exp Pathol2013https://conductscience.org/library/papers/23330003PubMed
229794465Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy.Cell Physiol Biochem2018https://conductscience.org/library/papers/29794465PubMed
333045061PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance.J Exp Med2021https://conductscience.org/library/papers/33045061PubMed
432345648Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.Clin Cancer Res2020https://conductscience.org/library/papers/32345648PubMed
532716559Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer.Hepatology2021https://conductscience.org/library/papers/32716559PubMed
632265229CD226hiCD8+ T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy.Cancer Immunol Res2020https://conductscience.org/library/papers/32265229PubMed
731234588DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy.Cancers (Basel)2019https://conductscience.org/library/papers/31234588PubMed
829025772Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.Cancer Discov2017https://conductscience.org/library/papers/29025772PubMed
911437656The poliovirus receptor CD155 mediates cell-to-matrix contacts by specifically binding to vitronectin.Virology2001https://conductscience.org/library/papers/11437656PubMed
1025934860PD-1 upregulated on regulatory T cells during chronic virus infection enhances the suppression of CD8+ T cell immune response via the interaction with PD-L1 expressed on CD8+ T cells.J Immunol2015https://conductscience.org/library/papers/25934860PubMed
1133224630TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer.Oncoimmunology2020https://conductscience.org/library/papers/33224630PubMed
1232591463IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.Clin Cancer Res2020https://conductscience.org/library/papers/32591463PubMed
1332269065Differential expression of the T-cell inhibitor TIGIT in glioblastoma and MS.Neurol Neuroimmunol Neuroinflamm2020https://conductscience.org/library/papers/32269065PubMed
1428434648Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.Lancet2017https://conductscience.org/library/papers/28434648PubMed
1528258692LAG3 (CD223) as a cancer immunotherapy target.Immunol Rev2017https://conductscience.org/library/papers/28258692PubMed
1620331633Overexpression of Necl-5 correlates with unfavorable prognosis in patients with lung adenocarcinoma.Cancer Sci2010https://conductscience.org/library/papers/20331633PubMed
1722427644The TIGIT/CD226 axis regulates human T cell function.J Immunol2012https://conductscience.org/library/papers/22427644PubMed
1830659055Mouse PVRIG Has CD8+ T Cell-Specific Coinhibitory Functions and Dampens Antitumor Immunity.Cancer Immunol Res2019https://conductscience.org/library/papers/30659055PubMed
1917875681The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells.Cancer Res2007https://conductscience.org/library/papers/17875681PubMed
2033781741TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma.Cell Mol Gastroenterol Hepatol2021https://conductscience.org/library/papers/33781741PubMed

See all 101 referencesDownload CSV of references

Cited by168

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 199 citations.

PMIDTitleJournalYearIn PapersSource
42969235TARBP2 facilitates renal cell carcinoma immune escape by suppressing 53BP1 phase separation to upregulate B7-H3.J Clin Invest2026https://conductscience.org/library/papers/42969235PubMed
42968166Checkpoint-checkpoint combinations in cancer: from mechanistic rationale to translational impact.J Transl Med2026https://conductscience.org/library/papers/42968166PubMed
42944788CD226⁺TIGIT⁺ MAIT cells exhibit an increased relative frequency and a checkpoint-enriched phenotype in Sjögren's disease.Clin Rheumatol2026https://conductscience.org/library/papers/42944788PubMed
42940206Phenotypic Landscape of Programmed Death and TIGIT/CD155/DNAM-1 Pathways in NK Cells in Ovarian Cancer.Biomedicines2026https://conductscience.org/library/papers/42940206PubMed
42719683Tumor microenvironment-mediated resistance to immune checkpoint inhibitors in non-small cell lung cancer: Mechanisms, combination strategies and clinical perspectives (Review).Mol Clin Oncol2026https://conductscience.org/library/papers/42719683PubMed
42694449The PVR-TIGIT/CD96/CD226 axis: a novel immune checkpoint target in ovarian cancer.Front Immunol2026https://conductscience.org/library/papers/42694449PubMed
42675035Regulatory T cell induction strategies and applications in the treatment of immune and non-immune diseases.Signal Transduct Target Ther2026https://conductscience.org/library/papers/42675035PubMed
42654087The Right Key, the Wrong Lock: TIGIT Checkpoint Blockade and the Road to Precision Immunotherapy.Pharmaceutics2026https://conductscience.org/library/papers/42654087PubMed
42486610Intratumoral TIGIT blockade augments antitumor responses and bypasses increased functionality of peripheral TIGIT+ NK cells in mouse and human models of bone and soft tissue sarcoma.J Immunother Cancer2026https://conductscience.org/library/papers/42486610PubMed
42389526Fusion protein-mediated costimulation in engineered T cells: from intrinsic signaling to tumor microenvironment rewiring.Front Immunol2026https://conductscience.org/library/papers/42389526PubMed
42382468PD-1/TIGIT CD4⁺ T-Cell Signature for Risk Stratification of Post-Weaning Mortality in Venoarterial Extracorporeal Membrane Oxygenation Patients.J Inflamm Res2026https://conductscience.org/library/papers/42382468PubMed
42353619Advancements in Immune Checkpoint-Based Immunotherapy for Triple-Negative Breast Cancer.Curr Issues Mol Biol2026https://conductscience.org/library/papers/42353619PubMed
42353092Beyond PD-1/PD-L1: Reprogramming the Gynecologic Tumor Microenvironment by Targeting TIGIT and Myeloid Suppression.Int J Mol Sci2026https://conductscience.org/library/papers/42353092PubMed
42338241Immune Checkpoints in Leukaemia as Gatekeepers of Immuno-Modulation.Immunology2026https://conductscience.org/library/papers/42338241PubMed
42317269Precision immuno-oncology in oral cancer: latest trends in biomarkers, novel drug development and nanoparticle-based therapeutic platforms.Front Cell Dev Biol2026https://conductscience.org/library/papers/42317269PubMed
42249376Insight of immune checkpoint blockades in melanoma: mechanism and clinical translation.Mol Cancer2026https://conductscience.org/library/papers/42249376PubMed
42237330TRIM71 suppresses cervical cancer progression by inhibiting Nectin4-mediated Wnt/β-catenin signaling.Biol Direct2026https://conductscience.org/library/papers/42237330PubMed
42176073Breakthroughs in HBV-related HCC Therapy: The Unmatched Potential of Immune Checkpoint Inhibitors.Curr Treat Options Oncol2026https://conductscience.org/library/papers/42176073PubMed
42174730CD155 and its receptors in glioma: prospects for emerging immune checkpoint inhibitors.Acta Neuropathol Commun2026https://conductscience.org/library/papers/42174730PubMed
42136664The mechanisms of regulatory T cells in the immune microenvironment of multiple myeloma and clinical significance.Front Immunol2026https://conductscience.org/library/papers/42136664PubMed

See all 168 cited byDownload CSV of cited by

Genes37

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CCR81237PubTator's text mininghttps://conductscience.org/library/genes/1237NCBI Gene
CD22610666PubTator's text mininghttps://conductscience.org/library/genes/10666NCBI Gene
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CD28940PubTator's text mininghttps://conductscience.org/library/genes/940NCBI Gene
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920NCBI Gene
CD80941PubTator's text mininghttps://conductscience.org/library/genes/941NCBI Gene
CD86942PubTator's text mininghttps://conductscience.org/library/genes/942NCBI Gene
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
CD9610225PubTator's text mininghttps://conductscience.org/library/genes/10225NCBI Gene
CTAG1A246100PubTator's text mininghttps://conductscience.org/library/genes/246100NCBI Gene
CTLA41493PubTator's text mininghttps://conductscience.org/library/genes/1493NCBI Gene
EPHB22048PubTator's text mininghttps://conductscience.org/library/genes/2048NCBI Gene
FGL210875PubTator's text mininghttps://conductscience.org/library/genes/10875NCBI Gene
FOXP350943PubTator's text mininghttps://conductscience.org/library/genes/50943NCBI Gene
HAVCR284868PubTator's text mininghttps://conductscience.org/library/genes/84868NCBI Gene
HLA-G3135PubTator's text mininghttps://conductscience.org/library/genes/3135NCBI Gene
IFNG3458PubTator's text mininghttps://conductscience.org/library/genes/3458NCBI Gene
IL103586PubTator's text mininghttps://conductscience.org/library/genes/3586NCBI Gene
IL12B3593PubTator's text mininghttps://conductscience.org/library/genes/3593NCBI Gene
IL153600PubTator's text mininghttps://conductscience.org/library/genes/3600NCBI Gene

See all 37 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34367161

GET https://conductscience.org/api/papers/v1/34367161/references?page=2